WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H412146
CAS#: 136533-74-9
Description: BN 52211 is a newly synthesized aza alkyl lysophosplipid of MW 536. BN 52211 is a phospholipid compound with direct cytotoxic and immunomodulatory activity against a variety of human tumour cell lines
Hodoodo Cat#: H412146
Name: BN 52211
CAS#: 136533-74-9
Chemical Formula: C28H61N2O5P
Exact Mass: 536.43
Molecular Weight: 536.779
Elemental Analysis: C, 62.65; H, 11.45; N, 5.22; O, 14.90; P, 5.77
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: BN-52211; BN52211; BN 52211
IUPAC/Chemical Name: 3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium, 4-hydroxy-7-methoxy-N,N,N,9-tetramethyl-, hydroxide, inner salt, 4-oxide
InChi Key: IMBDJLSSCGCJMU-UHFFFAOYSA-N
InChi Code: InChI=1S/C28H61N2O5P/c1-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-29(2)26-28(33-6)27-35-36(31,32)34-25-24-30(3,4)5/h28H,7-27H2,1-6H3
SMILES Code: CCCCCCCCCCCCCCCCCCN(C)CC(OC)COP(OCC[N+](C)(C)C)([O-])=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 536.78 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Gan XH, Bonavida B. Preferential induction of TNF-alpha and IL-1beta and inhibition of IL-10 secretion by human peripheral blood monocytes by synthetic aza-alkyl lysophospholipids. Cell Immunol. 1999 May 1;193(2):125-33. doi: 10.1006/cimm.1999.1457. PMID: 10222054.
2: Diomede L, Piovani B, Re F, Principe P, Colotta F, Modest EJ, Salmona M. The induction of apoptosis is a common feature of the cytotoxic action of ether- linked glycerophospholipids in human leukemic cells. Int J Cancer. 1994 Jun 1;57(5):645-9. doi: 10.1002/ijc.2910570506. PMID: 8194871.
3: Principe P, Broquet C, Paull K, Grever M, Coulomb H, Huchet M, Menciahuerta J, Braquet P. New antineoplastic aza-phospholipids - synthesis, in-vitro cytotoxicity and differential cellular-sensitivity against 70 human tumor-cell lines. Int J Oncol. 1994 Jan;4(1):29-36. PMID: 21566885.
4: Principe P, Sidoti C, Coulomb H, Broquet C, Braquet P. Tumor cell kinetics following long-term treatment with antineoplastic ether phospholipids. Cancer Detect Prev. 1994;18(5):393-400. PMID: 7812986.
5: Diomede L, Principe P, Domingo M, Broquet C, Chabrier P, Braquet P, Salmona M. Effect of paf antagonists on the cytotoxic activity of antineoplastic ether phospholipids. Int J Oncol. 1993 May;2(5):777-80. doi: 10.3892/ijo.2.5.777. PMID: 21573625.
6: Pignol B, Chaumeron S, Coulomb H, Maisonnet T, Vandamme B, Broquet C, Mencia- Huerta JM, Braquet P. Immunomodulatory activity of two new aza alkyl phospholipid antineoplastic drugs. Anticancer Drugs. 1992 Dec;3(6):599-608. doi: 10.1097/00001813-199212000-00007. PMID: 1288731.
7: Principe P, Coulomb H, Broquet C, Braquet P. Evaluation of combinations of antineoplastic ether phospholipids and chemotherapeutic drugs. Anticancer Drugs. 1992 Dec;3(6):577-87. doi: 10.1097/00001813-199212000-00004. PMID: 1288728.
8: Sidoti C, Principe P, Vandamme B, Broquet C, Braquet P. Cytostatic activity of new synthetic anti-tumor aza-alkyllysophospholipids. Int J Cancer. 1992 Jul 9;51(5):712-7. doi: 10.1002/ijc.2910510509. PMID: 1612779.
9: Morimoto H, Broquet C, Principe P, Mencia-Huerta JM, Braquet P, Bonavida B. Cytotoxic activity of synthetic aza alkyl lysophospholipids against drug sensitive and drug resistant human tumor cell lines. Anticancer Res. 1991 Nov- Dec;11(6):2223-9. PMID: 1776863.